Diese Website verwendet Cookies. Durch Ihre Nutzung unserer Website erklären Sie sich mit der Verwendung von Cookies einverstanden. Ein Cookie ist eine kleine Textdatei, die von den Seiten dieser Website an Ihren Browser gesendet und auf der Festplatte Ihres Computers gespeichert wird. Ihr Webbrowser sendet diese Cookies mit den Informationen zu Ihrem letzten Besuch bei jedem weiteren Besuch zurück an unsere Website. More information
Diese Nachricht ausblenden
Sysmex Austria
Menu
Sysmex Austria Unternehmen News & Events News OSNA for lung cancer – the newest…

OSNA for lung cancer – the newest addition to our oncology portfolio

OSNA, a molecular assay for accurate detection of lymph node metastases, is now available for lung cancer!

Sysmex announces the extension of the CE-mark for this new cancer application. Besides lung cancer, OSNA (One-Step Nucleic acid Amplification) is also widely used in breast, colon and gastric cancer.

Lung cancer is the biggest cancer killer with 1.8 million deaths worldwide and a survival rate of only 19% at five years after diagnosis. One main reason for this high mortality rate is the difficulty in detecting lung cancer in early stages. Fortunately, screening programmes are emerging that help diagnose patients sooner, which can lead to earlier therapy and potentially improve survival. At present, even if patients are diagnosed at an operable stage, up to 30% face recurrence after surgery. This is in part due to occult metastases in the lymph nodes that are missed by standard histology, which analyses only a small portion of the node.

Sysmex is excited to offer a fast, molecular whole-node analysis for lung cancer with OSNA. It provides nodal staging and prognosis accuracy as well as an improved basis for personalised intra- and post-operative treatment decisions.
The clinical trend is moving toward the de-escalation of surgical treatment in suited patients. Ongoing evaluations with OSNA are assessing the feasibility of intra-operative lymph node analysis to potentially reduce surgical radicality. Consequently, this would lead to improving patient quality of life and reducing associated morbidities, such as poor pulmonary and cardiac function.

OSNA for lung cancer will be officially launched on 20 December 2019. For more information about OSNA, visit www.sysmex-europe.com/osna.

 

About Sysmex

Sysmex aims to shape the advancement of healthcare by providing healthcare professionals around the world with a broad range of medical diagnostics products and solutions. Our total solutions combine highly dependable, multi-functional and easy-to-operate instruments, a variety of reagents, software that can consolidate testing data, and reliable service and support. Sysmex Europe GmbH, located near Hamburg, Germany, is a subsidiary of the Sysmex Corporation in Kobe, Japan. From our European headquarters, we serve our affiliates, distributors and customers throughout EMEA. For more information on how we are lighting the way with diagnostics, visit www.sysmex-europe.com.

Back to overview
Copyright © Sysmex Europe GmbH. All rights reserved.